Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2008 Jul 18.
Published in final edited form as: Neurosci Lett. 2007 Jun 17;422(3):193–197. doi: 10.1016/j.neulet.2007.06.021

Lrrk2 mutations in South America

A study of Chilean Parkinson's disease

Carolina Perez-Pastene 1, Stephanie A Cobb 2, Fernando Díaz-Grez 1, Mary M Hulihan 2, Marcelo Miranda 3,4, Pablo Venegas 3, Osvaldo Trujillo Godoy 3, Jennifer M Kachergus 2, Owen A Ross 2, Luis Layson 5, Matthew J Farrer 2, Juan Segura-Aguilar 1,*
PMCID: PMC1986707  NIHMSID: NIHMS28302  PMID: 17614198

Abstract

Pathogenic substitutions in the leucine-rich repeat kinase 2 protein (Lrrk2), R1441G and G2019S, are a prevalent cause of autosomal dominant and sporadic Parkinson's disease in the Northern Spanish population. In this study we examined the frequency of these two substitutions in 166 Parkinson's disease patients and 153 controls from Chile, a population with Spanish/European-Amerindian admixture. Lrrk2 R1441G was not observed, however Lrrk2 G2019S was detected in one familial and four sporadic Parkinson's disease patients. These findings suggest Lrrk2 G2019S may play an important role in Parkinson's disease on the South American Continent and further studies are now warranted.

Keywords: LRRK2; Parkinson's disease; mutation, Amerindian


Amino acid substitutions in the leucine-rich repeat kinase 2 (Lrrk2) protein are frequent cause of parkinsonism in ethnically-defined populations [13, 18, 20]. Recently a common variant (Lrrk2 G2385R), observed only on the Asian continent, was identified as a ‘risk-factor’ for Parkinson's disease (PD)[4, 5]. Similarly the Lrrk2 R1441G substitution has only been observed in the Basque region of Northern Spain and appears in 16% of familial and 4% of sporadic patients with PD [8, 20]. Lrrk2 G2019S is also present in Spain and Portugal in as high as 6% of familial and 3% of sporadic PD patients [3, 6, 9, 15], and is geographically widespread throughout Europe and North America [12]. Lrrk2 G2019S is most frequent in Northern Africa Arabs where it is found in up to 42% of familial and 41% of sporadic patients with PD [10, 11, 13].

Given the influence of the Spanish Diaspora in South America we reasoned both Lrrk2 R1441G and G2019S may be prevalent causes of PD in this continent. Spanish conquistadores arrived in Chile in 1549 to an Amerindian population of approximately 3 million people. Today about 0.5 million indigenous Amerindians remain with the majority of the population composed of Spanish/European-Amerindian admixture. In Chile, allele frequencies for genetic markers are known to vary with more alleles of European origin in higher socioeconomic stratum, while native Amerindian alleles are more prevalent in the lower socioeconomic stratum [2, 23].

Our sample originates from the Chilean capital, Santiago and consists of a total of 137 sporadic and 29 familial PD patients (93 female and 73 male; 69 ± 9 years of age) and 153 controls (104 female and 49 male; 61 ± 8 years of age). Interestingly, although PD has a higher prevalence in males, a higher proportion of females agreed to participate in this study than males, although no bias was shown towards female inclusion by the authors. Subjects were recruited through a patient's organization, ‘Parkinson's Liga’, and referred by participating neurologists of the Hospital Barros Luco Trudeau. All patients were specifically diagnosed by neurologists and confirmed as having idiopathic PD, presenting at least two of four cardinal signs: bradykinesia, rest tremor, rigidity, and postural reflex impairment group [7]. Exclusion criteria for a diagnosis of idiopathic PD disease were the use of medications (e.g. phenothiazines) during the 12 months preceding symptom onset; MRI or CT evidence of multiple cerebrovascular events prior to symptom onset; or evidence of another known cause of parkinsonism (e.g. history of brain tumor or encephalitis); or atypical PD presentation. Control subjects are healthy volunteers from the same geographic area and were examined by a neurologist to confirm the absence of any neurological disease. All subjects who participate in this study report Spanish-Amerindian ancestry. Spanish-Amerindian is the major ethnic group of the Chilean population and direct descendants of European genetic background were not included in this study.

Ethical approval of the research was obtained from the Ethical Committee of the Faculty of Medicine, University of Chile and all study subjects gave informed consent. All experiments on human subjects were conducted in accordance with the Declaration of Helsinki (http://www.wma.net).

DNA was isolated from peripheral blood lymphocytes for all subjects, using the Genomic Prep DNA Isolation Kit (Amersham Pharmacia Biotech) following the manufacturer's instructions. DNA was genotyped for the exon 31 LRRK2 4321C>G (R1441G) and exon 416055G>A (G2019S) mutations using ABI “by-design” probes and analysis was performed using SDS 2.2.2 software on an ABI 7900 (Applied Biosystems, CA). For the assay, 1 μl of DNA was added to 2.5 μl of TaqMan Universal PCR Master Mix, 2.375 μl of water and 0.125 μl of probe; PCR amplification and single nucleotide polymorphism (SNP) genotyping was performed following the manufacturer's protocol (Applied Biosystems, CA). Positive and negative controls where included on all assay plates. Positive or ambiguous results were confirmed/resolved with direct sequencing using the sense and anti-sense primers on an ABI3100, as previously reported [14]. Haplotype analysis employing both microsatellite and single nucleotide polymorphic markers was performed on the Lrrk2 G2019S carriers as previously reported [12, 16].

The Lrrk2 G2019S substitution was found in 5 of 166 (3 %) patients with PD and in no control subjects, a frequency comparable to that observed in Spain and Portugal (3−6%) [3, 6, 9, 15]. Unexpectedly this frequency is higher than observed in sporadic PD patients from Spain's neighboring European countries such as Italy (1%) [21]. It is also interesting that while present in both the North and South America continents, Lrrk2 G2019S appears to be rare/absent in countries (e.g. India and China) on the Asian continent [19, 22]. Epidemiologic studies find ∼14% of patients with PD have one or more 1st degree relatives with parkinsonism [17].Twenty-nine of our 166 PD patients (17.5 %) reported a family history of parkinsonism and only one of these harbor a Lrrk2 G2019S substitution. The fact that only one of five Lrrk2 G2019S carriers have a family history of disease probably reflects the age-associated penetrance of the mutation [12]. The Lrrk2 G2019S proband reported has a sister and grandmother suffering with PD.

All Lrrk2 G2019S carriers presented with typical L-Dopa responsive PD with relatively mild symptoms and a slow progression; the Hoehn and Yahr staging remained between 2−3 even with relatively long disease duration (∼20 years), which is consistent with past reports [1, 11] (Table 1). One of the sporadic Spanish-Amerindian patients is homozygous for Lrrk2 G2019S possibly reflecting the inter-marriage of closely related families, and suggests the mutation may be more frequent in specific Spanish-Amerindian groups. As in past studies, heterozygous and homozygous carriers have comparable ages at onset and clinical presentations [11](Table 1). All the Lrrk2 G2019S carriers in this study were found to carry the common reported haplotype, designated by SNPs rs28903073-A and rs10878245-C alleles, that is proposed to have arisen in Tunisia (Table 2) [12, 24].

Table 1.

Clinical characteristics of Parkinson's disease patients with Lrrk2 G2019S

Patient fPD-225 sPD-173 sPD-270 sPD-283 sPD-251
Mutation (Heterozygous) G2019S G2019S G2019S G2019S
Mutation (Homozygous) G2019S
Gender Male Female Female Female Female
Ethnic background Chilean/Amerindian Chilean/Amerindian Chilean/Amerindian Chilean/Amerindian Chilean/Amerindian
Family history Yes No No No No
Age-at-onset (year) 54 50 73 65 65
Last examination age (year) 72 69 75 67 77
Disease duration 18 20 2 4 12
L-Dopa response Yes Yes Yes Yes Yes
Drug induced dyskinesia Yes Yes Yes Yes Yes
Hoehn and Yahr staging 3 3 2 3 3
UPDRS part III motor 18 15 10 29 25
Typical PD symptoms Yes Yes Yes Yes Yes
Sign of dementia No No No No No

Table 2.

Chromosome 12q12 haplotype analysis of Chilean Parkinson's disease patients with Lrrk2 G2019S Chromosome 12 genotypes are shown for five Lrrk2 G2019S PD patients. LRRK2 6055 G>A (G2019S) is within exon 41 of the gene. The most parsimonious haplotype associated with disease, consistent with the consensus haplotype previously identified is in the right-hand column in bold. Marker positions (in base pairs) are from the UCSC database (March 2006; http://www.genome.ucsc.edu/). The haplotype is flanked by markers D12S2194 (Chr12q12: 38,738,008b; Allele ‘257’not shared by fPD-225) and D12S1701 (Chr12q12: 46,208,212b; homozygosity lost for sPD-251).

Marker Genomic Position fPD-225 sPD-173 sPD-270 sPD-283 sPD-251 (homozygous) Consensus sharing
D12S2194 38,738,008 249/261 257/261 249/257 249/257 257/257
D12S2514 38,873,791 285/291 291/291 291/297 291/297 291/291 291
ex5 rs10878245 38,918,058 C/C T/C T/C T/C C/C C
in t13 rs28903073 38,939,777 G/A G/A G/A G/A A/A A
in t30 D12S2516 38,989,235 254/254 254/254 254/254 254/254 254/254 254
in t34 rs11564205 39,000,276 A/G A/A A/A A/A AA A
ex41 G2019S 39,020,469 G/A G/A G/A G/A A/A A
ex43 rs10878405 39,028,521 A/A G/A G/A G/A A/A A
in t43 rs11176143 39,028,630 G/G G/G G/G G/G G/G G
in t45 D12S2518 39,034,806 154/154 154/154 154/170 154/170 154/154 154
ex49 rs3761863 39,044,919 C/C C/C T/C T/C CC C
D12S2519 39,116,760 132/140 132/132 132/132 132/132 132/132 132
D12S2520 39,120,028 260/260 257/260 251/260 251/260 260/260 260
D12S2521 39,128,575 327/359 359/359 359/367 359/371 359/359 359
D12S2522 39,132,267 287/297 297/297 297/299 297/299 297/297 297
D12S2517 39,282,898 192/202 186/192 192/192 190/192 192/192 192
D12S1048 39,312,654 211/214 211/214 214/223 214/226 214/214 214
D12S1701 46,208,212 95/101 95/101 95/97 89/95 95/103

The Lrrk2 R1441G substitution was not present in this sample from the Chilean population and this may indicate that this variant is restricted to the northern regions of Spain due to a more recent mutational event, or that the majority of conquistadores in Chile were from the south of Spain. Geographically Chile is located on the South-West coast of the South American Continent, for which our sample may not be representative (Figure 1). Santiago is in the center of Chile, a city of about 5−6 million inhabitants with a heterogeneous population and areas of marked European influence. However, all subjects in the present study were drawn from areas with low economic and educational attainment with considerable Spanish-Amerindian admixture [23].

Figure 1.

Figure 1

The continent of South America

The evidence of the common founder haplotype, as observed throughout North Africa, Europe (including Spain) and North America supports the hypothesis that this mutation was brought to the Chilean population by Spanish settlers. Given the frequency of Lrrk2 G2019S discovered, and the European/African founder haplotype, we recommend further studies of Lrrk2 variants in community-based samples from Chile and South America. Given population specificity of Lrrk2 substitutions complete gene sequence analysis in Amerindian patients with familial parkinsonism is warranted.

Acknowledgement

This work is supported by FONDECYT # 1061083. The Department of Neuroscience at the Mayo Clinic Jacksonville is a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 #NS40256) and is funded by the National Institute of Aging (P01 #AG17216).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol. 2005;57:762–5. doi: 10.1002/ana.20456. [DOI] [PubMed] [Google Scholar]
  • 2.Acuna M, Jorquera H, Cifuentes L, Armanet L. Frequency of the hypervariable DNA loci D18S849, D3S1744, D12S1090 and D1S80 in a mixed ancestry population of Chilean blood donors. Genet Mol Res. 2002;1:139–46. [PubMed] [Google Scholar]
  • 3.Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, Oliveira CR, Cunha L, Hardy J, Singleton A. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov Disord. 2005;20:1653–5. doi: 10.1002/mds.20682. [DOI] [PubMed] [Google Scholar]
  • 4.Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics. 2006;7:133–8. doi: 10.1007/s10048-006-0041-5. [DOI] [PubMed] [Google Scholar]
  • 5.Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord. 2007;13:89–92. doi: 10.1016/j.parkreldis.2006.12.001. [DOI] [PubMed] [Google Scholar]
  • 6.Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol. 2006;63:377–82. doi: 10.1001/archneur.63.3.377. [DOI] [PubMed] [Google Scholar]
  • 7.Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–9. doi: 10.1001/archneur.56.1.33. [DOI] [PubMed] [Google Scholar]
  • 8.Gonzalez-Fernandez MC, Lezcano E, Ross OA, Gomez-Esteban JC, Gomez-Busto F, Velasco F, Alvarez-Alvarez M, Rodriguez-Martinez MB, Ciordia R, Zarranz JJ, Farrer MJ, Mata IF, de Pancorbo MM. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord. 2007 doi: 10.1016/j.parkreldis.2007.04.003. [DOI] [PubMed] [Google Scholar]
  • 9.Infante J, Rodriguez E, Combarros O, Mateo I, Fontalba A, Pascual J, Oterino A, Polo JM, Leno C, Berciano J. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett. 2006;395:224–6. doi: 10.1016/j.neulet.2005.10.083. [DOI] [PubMed] [Google Scholar]
  • 10.Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, Leppert D, Surh L, Reeves KH, Thomas S, Ragone L, Hattori N, Pahwa R, Jankovic J, Nance M, Freeman A, Gouider-Khouja N, Kefi M, Zouari M, Ben Sassi S, Ben Yahmed S, El Euch-Fayeche G, Middleton L, Burn DJ, Watts RL, Hentati F. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22:55–61. doi: 10.1002/mds.21180. [DOI] [PubMed] [Google Scholar]
  • 11.Ishihara L, Warren L, Gibson R, Amouri R, Lesage S, Durr A, Tazir M, Wszolek ZK, Uitti RJ, Nichols WC, Griffith A, Hattori N, Leppert D, Watts R, Zabetian CP, Foroud TM, Farrer MJ, Brice A, Middleton L, Hentati F. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol. 2006;63:1250–4. doi: 10.1001/archneur.63.9.1250. [DOI] [PubMed] [Google Scholar]
  • 12.Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet. 2005;76:672–80. doi: 10.1086/429256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006;354:422–3. doi: 10.1056/NEJMc055540. [DOI] [PubMed] [Google Scholar]
  • 14.Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics. 2005;6:171–7. doi: 10.1007/s10048-005-0005-1. [DOI] [PubMed] [Google Scholar]
  • 15.Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, Blazquez M, Guisasola LM, Salvador C, Martinez C, Farrer M, Alvarez V. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol. 2006;13:391–4. doi: 10.1111/j.1468-1331.2006.01256.x. [DOI] [PubMed] [Google Scholar]
  • 16.Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M, Alvarez V. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett. 2005;382:309–11. doi: 10.1016/j.neulet.2005.03.033. [DOI] [PubMed] [Google Scholar]
  • 17.McDonnell SK, Schaid DJ, Elbaz A, Strain KJ, Bower JH, Ahlskog JE, Maraganore DM, Rocca WA. Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study. Ann Neurol. 2006;59:788–95. doi: 10.1002/ana.20844. [DOI] [PubMed] [Google Scholar]
  • 18.Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006;354:424–5. doi: 10.1056/NEJMc055509. [DOI] [PubMed] [Google Scholar]
  • 19.Punia S, Behari M, Govindappa ST, Swaminath PV, Jayaram S, Goyal V, Muthane UB, Juyal RC, Thelma BK. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. Neurosci Lett. 2006;409:83–8. doi: 10.1016/j.neulet.2006.04.052. [DOI] [PubMed] [Google Scholar]
  • 20.Simon-Sanchez J, Marti-Masso JF, Sanchez-Mut JV, Paisan-Ruiz C, Martinez-Gil A, Ruiz-Martinez J, Saenz A, Singleton AB, Lopez de Munain A, Perez-Tur J. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord. 2006;21:1954–9. doi: 10.1002/mds.21114. [DOI] [PubMed] [Google Scholar]
  • 21.Squillaro T, Cambi F, Ciacci G, Rossi S, Ulivelli M, Malandrini A, Mencarelli MA, Mari F, Renieri A, Ariani F. Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease. J Hum Genet. 2007;52:201–4. doi: 10.1007/s10038-006-0105-2. [DOI] [PubMed] [Google Scholar]
  • 22.Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yih Y, Skipper L, Liu JJ. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett. 2005;384:327–9. doi: 10.1016/j.neulet.2005.04.103. [DOI] [PubMed] [Google Scholar]
  • 23.Valenzuela Y. On sociogenetic clines. Ethno Sociobiol. 1988;9:259–68. [Google Scholar]
  • 24.Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, Ragone L, Pahwa R, Jankovic J, Nance M, Freeman A, Watts RL, Hentati F. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2007 doi: 10.1016/j.parkreldis.2007.02.001. [DOI] [PubMed] [Google Scholar]

RESOURCES